The Androgen Deprivation Therapy ADT Market size is expected to grow at an annual average of 5% during 2021-2027. Androgen deprivation therapy (ADT), also known as androgen suppression therapy, is administered to men with prostate cancer. The pancreas is an androgen-dependent organ, and by providing ADT, it can provide treatment for advanced and metastatic disease. ADT is also used in combination with external beam radiation therapy (EBRT) to improve response to radiation in patients with moderate to high-risk prostate cancer. It is estimated that approximately 40% of patients diagnosed with prostate cancer will receive ADT within 6 months of diagnosis.
(Get 15% Discount on Buying this Report)
A full report of Androgen Deprivation Therapy ADT Market is available at: https://www.orionmarketreports.com/androgen-deprivation-therapy-adt-market/57770/
The following segmentation are covered in this report:
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Route of Administration
- Oral
- Injectable
Company Profile
- Pfizer
- Astellas Pharma
- Johnson and Johnson
- Novartis International
- Merck
- Veru
- Sanofi
- GlaxoSmithKline
- Bayer
- Orion
- AstraZeneca
The report covers the following objectives:
- Proliferation and maturation of trade in the global Androgen Deprivation Therapy ADT Market
- The market share of the global Androgen Deprivation Therapy ADT Market supply and demand ratio, growth revenue, supply chain analysis, and business overview.
- Current and future market trends that are influencing the growth opportunities and growth rate of the Androgen Deprivation Therapy ADT Market
- Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Androgen Deprivation Therapy ADT Market
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
